GLP-1 medicines may cut clot-related risks in chronically inflamed patients
A large real-world analysis suggests GLP-1 receptor agonists may offer clot-related and survival benefits in a chronically inflamed,…
The next goal for weight loss drugs? Fewer injections
For millions of people taking weight loss drugs, the next breakthrough may not be more weight loss. It…
Microbially modified bile acids influence sleep apnea outcomes
Studies in mice reveal a new target for potentially treating and preventing life-threatening cardiovascular complications in the millions…
Real-world study exposes suboptimal adherence to treat-to-target rheumatic strategies
EULAR – The European Alliance of Associations for Rheumatology – acknowledges the role of diverse real-world data to…
Could GLP-1 drugs help prevent breast cancer? New study points to a possible link
A major breast imaging study links GLP-1 agonists to lower breast cancer incidence, raising hopes for a new…
Novel PRRT approach shows promise in advanced neuroendocrine tumors
A new type of peptide receptor radionuclide therapy (PRRT) appears to be safe in metastatic neuroendocrine tumor patients…
Scientists rethink GLP-1 delivery to improve dosing, tolerability, and adherence
From microneedles to nanocarriers, researchers are rethinking how GLP-1 medicines could become longer-lasting, easier to tolerate, and more…
Researchers uncover possible cause of pain in neurofibromatosis type 1
Researchers at Cincinnati Children’s have identified a potential new way to relieve chronic pain linked to neurofibromatosis type…
Roswell Park scientists present five key cancer studies at clinical meeting
The research findings of experts from Roswell Park Comprehensive Cancer Center will be featured during the American Society…
NIH researchers discover how weight-loss drugs alter brain cells
A team of researchers at the National Institutes of Health (NIH) have unveiled new details about the events…
Polymer-based immunotherapies enhance tumor targeting and immune activation
Conventional immune checkpoint inhibitors, such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, can reinvigorate T cells but typically benefit less…
Molecular profiling initiative seeks to uncover late breast cancer recurrence mysteries
The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), in collaboration with the SWOG Cancer Research Network (SWOG), has launched a…